Yubo International Biotech Ltd (YBGJ)
YBGJ is quoted over the counter, not listed on an exchange. Yubo International Biotech Ltd files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | YBGJ, quoted over the counter |
| SEC CIK | 0000895464 |
| OTC Markets tier | OTCID (price source, 2026-11-13) |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Business address | Beijing, China |
| Incorporated in | NY |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time." | 10-Q 2026-11-10 |
| Cash and burn | $9K cash; operating cash flow -$105K a quarter. | Report 2026-09-30 |
| Shares outstanding | 170,420,790 (2026-11-10). | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | HCL,PLLC, Chicago, Illinois, United States; changed auditors 3 times in 24 months | 8-K 4.01 2026-01-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2027 2026-09-30 | $0 | -$188K | -$157 | $9K | No debt tags | $12K | 10-Q 2026-11-10 |
| Q1 2027 2026-06-30 | $0 | -$248K | -$84K | $12K | No debt tags | $12K | 10-Q 2026-08-14 |
| Q1 2027 2026-03-31 | $0 | -$273K | -$207K | $10K | No debt tags | $12K | 10-Q 2026-05-15 |
| Q3 2026 2025-12-31 | $12K | -$261K | -$129K | $8K | No debt tags | $12K | 10-K 2026-03-31 |
| Q2 2026 2025-09-30 | $0 | -$277K | -$308K | $11K | No debt tags | -$18 | 10-Q 2026-11-10 |
| Q1 2026 2025-06-30 | $0 | -$230K | -$14K | $10K | No debt tags | -$18 | 10-Q 2026-08-14 |
| Q1 2026 2025-03-31 | $0 | -$436K | -$392K | $10K | No debt tags | -$18 | 10-Q 2026-05-15 |
| Q3 2025 2024-12-31 | -$18 | -$147K | -$933K | $7K | No debt tags | $3K | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2022-11-16 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-01-16 |
| Latest proxy | DEF 14A | 2001-08-08 |
Source: SEC EDGAR submissions feed, 285 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier